Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chun, Nan-Hee | - |
dc.contributor.author | Wang, In-Chun | - |
dc.contributor.author | Lee, Min-Jeong | - |
dc.contributor.author | Jung, Yun-Taek | - |
dc.contributor.author | Lee, Sangkil | - |
dc.contributor.author | Kim, Woo-Sik | - |
dc.contributor.author | Choi, Guang J. | - |
dc.date.accessioned | 2024-01-08T06:57:50Z | - |
dc.date.available | 2024-01-08T06:57:50Z | - |
dc.date.issued | 2013-11 | - |
dc.identifier.issn | 0939-6411 | - |
dc.identifier.issn | 1873-3441 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69422 | - |
dc.description.abstract | The creation of co-crystals of various insoluble drug substances has been extensively investigated as a promising approach to improve their pharmaceutical performance. In this study, co-crystal powders of indomethacin and saccharin (IMC-SAC) were prepared by an anti-solvent (water) addition and compared with co-crystals by evaporation method. No successful synthesis of a pharmaceutical co-crystal powder via an anti-solvent approach has been reported. Among solvents examined, methanol was practically the only one that resulted in the formation of highly pure IMC-SAC co-crystal powders by anti-solvent approach. The mechanism of a preferential formation of IMC-SAC co-crystal to IMC was explained with two aspects: phase solubility diagram and solution complexation concept. Accordingly, the anti-solvent approach can be considered as a competitive route for producing pharmaceutical co-crystal powders with acceptable properties. (C) 2013 Elsevier By. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER | - |
dc.title | Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ejpb.2013.02.007 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, v.85, no.3, pp 854 - 861 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000330200800005 | - |
dc.identifier.scopusid | 2-s2.0-84889102250 | - |
dc.citation.endPage | 861 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 854 | - |
dc.citation.title | EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS | - |
dc.citation.volume | 85 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Co-crystal | - |
dc.subject.keywordAuthor | Indomethacin | - |
dc.subject.keywordAuthor | Saccharin | - |
dc.subject.keywordAuthor | Anti-solvent crystallization | - |
dc.subject.keywordAuthor | Mechanism | - |
dc.subject.keywordAuthor | Dissolution rate | - |
dc.subject.keywordPlus | PHARMACEUTICAL COCRYSTALS | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | DRUGS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.